Cargando…
Inhibiting the SUMO Pathway Represses the Cancer Stem Cell Population in Breast and Colorectal Carcinomas
Many solid cancers have an expanded CD44(+/hi)/CD24(−/low) cancer stem cell (CSC) population, which are relatively chemoresistant and drive recurrence and metastasis. Achieving a more durable response requires the development of therapies that specifically target CSCs. Recent evidence indicated that...
Autores principales: | Bogachek, Maria V., Park, Jung M., De Andrade, James P., Lorenzen, Allison W., Kulak, Mikhail V., White, Jeffrey R., Gu, Vivian W., Wu, Vincent T., Weigel, Ronald J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5161532/ https://www.ncbi.nlm.nih.gov/pubmed/27916539 http://dx.doi.org/10.1016/j.stemcr.2016.11.001 |
Ejemplares similares
-
Targeting the SUMO pathway as a novel treatment for anaplastic thyroid cancer
por: De Andrade, James P., et al.
Publicado: (2017) -
AP-2γ Is Required for Maintenance of Multipotent Mammary Stem Cells
por: Gu, Vivian W., et al.
Publicado: (2020) -
Transcriptional Regulation of the GPX1 Gene by TFAP2C and Aberrant CpG Methylation in Human Breast Cancer
por: Kulak, Mikhail V., et al.
Publicado: (2012) -
TFAP2C Governs the Luminal Epithelial Phenotype in Mammary Development and Carcinogenesis
por: Cyr, Anthony R, et al.
Publicado: (2014) -
The Polycomb Repressive Complex 2 Is a Potential Target of SUMO Modifications
por: Riising, Eva Madi, et al.
Publicado: (2008)